GlassScriptPhysician profile
Timothy D Woods
NPI 1053334516
$89,356.13
in general payments reported to CMS, 2019-2025
37 companies · $3,201 in 2025
The $3,201 reported for 2025 was more than what 86% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $1,958 · 2021: $9,280 · 2022: $1,208 · 2023: $22K · 2024: $36K · 2025: $3,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $48K · Food and Beverage: $6,544 · Consulting Fee: $3,900 · Travel and Lodging: $2,996 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $47,520.00 |
| Food and Beverage | $6,543.89 |
| Consulting Fee | $3,900.00 |
| Travel and Lodging | $2,995.66 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $64,380.31 | 2019-2025 | Da Vinci Surgical System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $6,180.00 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $5,885.79 | 2024-2025 | |
| Acelrx Pharmaceuticals, INC. | $4,592.37 | 2019 | |
| Davol INC. | $2,899.29 | 2019-2024 | |
| Ethicon US, LLC | $1,367.70 | 2019-2024 | Evarrest, Echelon Endopath, Stratafix |
| Depuy Synthes Sales INC. | $1,217.59 | 2022-2025 | Matrixrib, Xcm Biologic Tissue Matrix |
| Medical Device Business Services, INC. | $1,026.01 | 2019 | |
| Novo Nordisk INC | $375.39 | 2019-2025 | Wegovy |
| Kci USA, INC. | $246.59 | 2019-2023 | Abthera Advance |
| Zimmer Biomet Holdings, INC. | $155.66 | 2019 | |
| Medtronic, INC. | $147.50 | 2021-2025 | Signia, Maxtack |
| Smith+Nephew, INC. | $123.55 | 2019 | |
| Portola Pharmaceuticals, LLC | $105.98 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $97.75 | 2019-2024 | Bridion |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tela Bio, INC. | $72.25 | 2019-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Teleflex LLC | $55.63 | 2025 | Titan Sgs Bailout Chuck |
| Haemonetics Corporation | $37.42 | 2023 | Teg6s Hemostasis System |
| Allergan, INC. | $35.66 | 2019 | |
| Lilly USA, LLC | $34.65 | 2024-2025 | Zepbound |
| Csl Behring | $34.62 | 2019-2024 | Kcentra |
| Janssen Pharmaceuticals, INC | $32.47 | 2019 | |
| Advanced Accelerator Applications | $26.79 | 2019-2020 | |
| Daiichi Sankyo INC. | $24.67 | 2019 | |
| Mallinckrodt Enterprises LLC | $24.00 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $23.23 | 2023 | Exparel |
| Baxter Healthcare | $21.09 | 2019 | |
| Kls-Martin L.P. | $19.77 | 2019 | |
| Amarin Pharma, INC. | $19.06 | 2020 | |
| Kerecis Limited | $18.29 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Polynovo North America LLC | $16.69 | 2021 | |
| La Jolla Pharmaceutical Company | $13.64 | 2019 | |
| Currax Pharmaceuticals LLC | $13.51 | 2025 | Contrave |
| Cook Medical LLC | $12.28 | 2019 | |
| Boston Scientific Corporation | $11.17 | 2019 | |
| Endogastric Solutions, INC | $7.76 | 2023 | Esophyx |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Woods listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.